Genomics is transforming modern infectious disease surveillance, expanding our understanding of pathogen evolution, host–pathogen interactions, and antibiotic resistance. In turn, public health professionals are changing the methods they use to research, monitor, and prevent epidemics and pandemics of high-profile infectious diseases such as influenza, tuberculosis, Ebola, and more recently, coronavirus.
Traditional methods of assessing infectious agents include antibody-based testing, real-time PCR, pulsed field gel electrophoresis, and multilocus sequence typing. These methods are typically useful only for a small and defined number of organisms, and data analysis can be subjective. In contrast, next-generation sequencing (NGS) provides a universal, hypothesis-free method for infectious disease surveillance that may be used with viruses, bacteria, fungi, or parasites, and can replace the need for multiple tests.
The severe acute respiratory syndrome coronavirus COVID-19 outbreak is an important reminder that the global community must strengthen national and international programs for early detection and response to future disease outbreaks.
Illumina technology was used as part of front line testing to identify coronavirus. We have made our technology available globally to support applications and strategies to improve detection and to enhance our tracking of the epidemiology, evolution, and virulence of COVID-19.Read Article
Effective detection of coronavirus using a comprehensive targeted enrichment workflow.Read Application Note
A shotgun metagenomics sequencing workflow for effective detection and characterization of coronavirus strains.Read Application Note
A resource guide for detection and full genome sequencing of SARS-CoV-2 and a broad spectrum of respiratory viruses.Read More
The partnership aims to accelerate and improve testing for emerging public health threats like SARS-Cov-2.Read More
NGS technology enabled infectious disease experts to identify and characterize the genome of the novel coronavirus in China.Read Review
Chief Medical Officer, Phil Febbo, MD, discusses how public officials follow the path of the epidemic and what that means for tracking the spread of coronavirus mutations.Read More
This summary highlights recent peer-reviewed publications in which researchers used NGS to analyze viral populations, microbial pathogenesis, zoonotic reservoirs, the gut microbiome, and more.Read Review
Genomic analysis with NGS provides high-resolution information to distinguish pathogen strains that differ by as little as one single-nucleotide polymorphism (SNP). It also allows identification of both novel and known infectious agents.
Illumina NGS technology delivers rapid results and high-quality data that public health professionals are utilizing to identify, track, and respond to infectious disease outbreaks.